JP2023531069A5 - - Google Patents
Info
- Publication number
- JP2023531069A5 JP2023531069A5 JP2022580122A JP2022580122A JP2023531069A5 JP 2023531069 A5 JP2023531069 A5 JP 2023531069A5 JP 2022580122 A JP2022580122 A JP 2022580122A JP 2022580122 A JP2022580122 A JP 2022580122A JP 2023531069 A5 JP2023531069 A5 JP 2023531069A5
- Authority
- JP
- Japan
- Prior art keywords
- tau
- patient
- pharmaceutical composition
- binding member
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043872P | 2020-06-25 | 2020-06-25 | |
| US63/043,872 | 2020-06-25 | ||
| PCT/EP2021/067536 WO2021260193A1 (en) | 2020-06-25 | 2021-06-25 | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531069A JP2023531069A (ja) | 2023-07-20 |
| JP2023531069A5 true JP2023531069A5 (enExample) | 2024-07-01 |
Family
ID=76662499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580122A Pending JP2023531069A (ja) | 2020-06-25 | 2021-06-25 | アミロイドβ１－４２に結合する抗体を使用する軸索損傷の予防 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230287092A1 (enExample) |
| EP (1) | EP4171742A1 (enExample) |
| JP (1) | JP2023531069A (enExample) |
| KR (1) | KR20230026490A (enExample) |
| CN (1) | CN116547299A (enExample) |
| AU (1) | AU2021295605A1 (enExample) |
| BR (1) | BR112022026359A2 (enExample) |
| CA (1) | CA3187785A1 (enExample) |
| IL (1) | IL299215A (enExample) |
| WO (1) | WO2021260193A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2024015951A2 (en) * | 2022-07-15 | 2024-01-18 | Seq Biomarque, Llc | Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease |
| CN117624357B (zh) * | 2024-01-26 | 2024-03-22 | 南京诺唯赞医疗科技有限公司 | p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US151A (en) | 1837-03-25 | Spring-saddle | ||
| US5654A (en) | 1848-06-27 | Door-spring | ||
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| JP4531132B2 (ja) | 1995-06-02 | 2010-08-25 | ギリード・サイエンシズ・インコーポレーテッド | 増殖因子に対する高親和性オリゴヌクレオチドリガンド |
| EP2198292A4 (en) * | 2007-08-21 | 2010-09-08 | Univ Washington | IMPROVED MORBUS ALZHEIMER DIAGNOSIS |
| SMT202000340T1 (it) * | 2012-10-15 | 2020-07-08 | Medimmune Ltd | Anticorpi contro il beta amiloide |
| CA2926092A1 (en) * | 2013-10-24 | 2015-04-30 | Nanosomix, Inc. | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders |
| RS64263B1 (sr) | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| WO2017158064A1 (en) * | 2016-03-15 | 2017-09-21 | Astrazeneca Ab | Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta |
| WO2017193115A1 (en) * | 2016-05-06 | 2017-11-09 | Nanosomix, Inc. | Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders |
| CA3032692A1 (en) * | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
| CN110168375B (zh) * | 2016-11-10 | 2022-09-16 | 脑生物标记解决方案哥德堡公司 | 检测个体罹患神经退行性疾病风险的方法 |
| SG11202112329RA (en) * | 2019-05-21 | 2021-12-30 | Ac Immune Sa | Anti-abeta vaccine therapy |
-
2021
- 2021-06-25 WO PCT/EP2021/067536 patent/WO2021260193A1/en not_active Ceased
- 2021-06-25 JP JP2022580122A patent/JP2023531069A/ja active Pending
- 2021-06-25 KR KR1020237002535A patent/KR20230026490A/ko active Pending
- 2021-06-25 CN CN202180052963.4A patent/CN116547299A/zh active Pending
- 2021-06-25 BR BR112022026359A patent/BR112022026359A2/pt unknown
- 2021-06-25 IL IL299215A patent/IL299215A/en unknown
- 2021-06-25 US US18/011,965 patent/US20230287092A1/en active Pending
- 2021-06-25 EP EP21735716.9A patent/EP4171742A1/en active Pending
- 2021-06-25 AU AU2021295605A patent/AU2021295605A1/en active Pending
- 2021-06-25 CA CA3187785A patent/CA3187785A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531069A5 (enExample) | ||
| RU2008129080A (ru) | Средства и способы лечения опухолевых заболеваний | |
| JP2023548858A5 (enExample) | ||
| JP2018529634A5 (enExample) | ||
| KR20080042905A (ko) | 항-ｃｄ３ 항체 조제물 | |
| JP2023520516A5 (enExample) | ||
| US20230030950A1 (en) | Treatment of neurodegenerative diseases using ultrasound and amyloid-beta antibodies | |
| JP2019512472A5 (enExample) | ||
| KR20190077306A (ko) | 항-o2 항체 및 이의 용도 | |
| US20240398978A1 (en) | Compositions and Methods for Treating Dopamine Disorders | |
| JP6560808B2 (ja) | 抗（＋）メタンフェタミンモノクローナル抗体 | |
| US20220127346A1 (en) | Methods of Safe Administration of Anti-Tau Antibody | |
| KR102460465B1 (ko) | 알츠하이머병（ａｄ）의 치료 및 예방 | |
| TW202233666A (zh) | 減少人類對象中之ｔａｕ的方法 | |
| US20240158486A1 (en) | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF | |
| KR20260020387A (ko) | 이중특이성 항-아베타/TfR 항체의 치료적 용도 | |
| CA2946931A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| CA3135181A1 (en) | Fusion constructs and uses thereof | |
| CN107249630A (zh) | 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重 | |
| US20240360215A1 (en) | Anti-cd19 antibody in the treatment of cns lymphoma | |
| CN106659738A (zh) | 阿尔茨海默病(ad)的治疗和预防 | |
| TH2101002581A (th) | วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn | |
| US20140130191A1 (en) | Methods for treating immune-mediated diseases of the nervous system administering a compound comprising agents that inhibit prokineticin receptors activity | |
| HK40102408B (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| HK40102408A (zh) | 含抗lag-3抗体的药物组合物及其用途 |